Market Overview - The Nikkei share average closed at 44,550.85, down 0.85%, marking its lowest close since September 11, and has lost for four consecutive sessions [1][5] - The broader Topix index fell 1.37% to 3,094.74 [1][5] - A significant sell-off occurred as investors took profits from the recent rally that had boosted the Nikkei [1][2] Company Performance - Tokyo Electron, a chip-making equipment manufacturer, experienced a notable surge of 27.6% in September, its largest monthly gain since February 2024, contributing significantly to the Nikkei's record high last month [3][5] - On the day of the report, Tokyo Electron's stock fell by 2.09%, while SoftBank Group, a technology start-up investor, declined by 2.38%, becoming the largest detractors from the Nikkei [4][5] - Advantest, a chip-testing equipment maker, saw a slight increase of 0.17%, following overnight gains in the U.S. chip index [5] Sector Performance - The Tokyo Stock Exchange's 33 industry sub-indexes saw declines, with the bank index dropping 3.07%, making it the worst-performing sector [5] - Major banks such as Mitsubishi UFJ Financial Group and Mizuho Financial Group fell by 3.17% and 3.83%, respectively [5] - The real estate firm index decreased by 2.83%, while drug manufacturers rose by 0.95%, with Otsuka Holdings and Chugai Pharmaceutical increasing by 5.22% and 3.86%, respectively [5] - Overall, 91% of the 1,600 stocks trading on the TSE's prime market fell, while only 7% rose [5]

We are seeing Swiss pharmaceuticals react to the, I feel like it's the tariffs sentiment that's hitting Swiss stocks altogether, but also the drug pricing story from Friday as well. Just walk us through how these drug makers have responded, how much room to manoeuvre they actually have. So firstly, there's a lot of uncertainty still for Swiss pharma companies.So the 39% is not actually going to hit them immediately. They sort of have a short stay of execution in some ways, but at the same time they know tha ...